Melissa Wigderson

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.

J. McMurray, H. Parving, G. Bakris, 2018 .

Baseline characteristics and enrichment results from the SONAR trial

J. McMurray, H. Parving, G. Bakris, 2018, Diabetes, obesity & metabolism.

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

R. Finkel, K. Strauss, J. Mendell, 2022, Nature Medicine.

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

J. McMurray, H. Parving, G. Bakris, 2018, Diabetes, obesity & metabolism.

Intravenous and Intrathecal Onasemnogene Abeparvovec Gene Therapy in Symptomatic and Presymptomatic Spinal Muscular Atrophy: Long-Term Follow-Up Study (S34.002)

Y. Chien, J. Day, B. Darras, 2023, Wednesday, April 26.